Skip to Content

PARP inhibitor niraparib as first-line treatment in patients with prostate cancer

FIRST STUDY RESULTS: Addition of niraparib to abiraterone acetate and prednisone improves progression-free survival in patients with metastatic castration-resistant prostate cancer.

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top